JPWO2023280880A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023280880A5 JPWO2023280880A5 JP2024500088A JP2024500088A JPWO2023280880A5 JP WO2023280880 A5 JPWO2023280880 A5 JP WO2023280880A5 JP 2024500088 A JP2024500088 A JP 2024500088A JP 2024500088 A JP2024500088 A JP 2024500088A JP WO2023280880 A5 JPWO2023280880 A5 JP WO2023280880A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific antibody
- antibody
- intact
- intact bispecific
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21183796 | 2021-07-05 | ||
| EP21183796.8 | 2021-07-05 | ||
| EP21184105.1A EP4116330A1 (en) | 2021-07-05 | 2021-07-06 | Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
| EP21184105.1 | 2021-07-06 | ||
| PCT/EP2022/068634 WO2023280880A1 (en) | 2021-07-05 | 2022-07-05 | Multispecific antibodies binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024524527A JP2024524527A (ja) | 2024-07-05 |
| JPWO2023280880A5 true JPWO2023280880A5 (https=) | 2025-05-12 |
| JP2024524527A5 JP2024524527A5 (https=) | 2025-05-12 |
Family
ID=82656531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500088A Pending JP2024524527A (ja) | 2021-07-05 | 2022-07-05 | がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240239916A1 (https=) |
| EP (1) | EP4330289A1 (https=) |
| JP (1) | JP2024524527A (https=) |
| WO (1) | WO2023280880A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| EP4684803A1 (en) | 2024-07-25 | 2026-01-28 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Antibody conjugated chemical inducers of degradation of rbm39 and therapeutic uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4419399C1 (de) | 1994-06-03 | 1995-03-09 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| CA2414148A1 (en) * | 2002-12-30 | 2004-06-30 | William Herman | Targeted ligands |
| WO2013189516A1 (en) * | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| US11820832B2 (en) * | 2014-07-25 | 2023-11-21 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| TWI823906B (zh) * | 2018-03-09 | 2023-12-01 | 美商艾吉納斯公司 | 抗-cd73 抗體及其使用方法 |
-
2022
- 2022-07-05 US US18/577,197 patent/US20240239916A1/en active Pending
- 2022-07-05 JP JP2024500088A patent/JP2024524527A/ja active Pending
- 2022-07-05 EP EP22744699.4A patent/EP4330289A1/en active Pending
- 2022-07-05 WO PCT/EP2022/068634 patent/WO2023280880A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Folli et al. | Tumor‐necrosis factor can enhance radio‐antibody uptake in human colon carcinoma xenografts by increasing vascular permeability | |
| Miller et al. | Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody | |
| EP0252741B1 (en) | Use of a monoclonal antibody against the 17-1A antigen for the manufacture of a medicament for the treatment of a gastrointestinal tumor | |
| EP1200098A2 (en) | Combined preparations comprising daunorubicin derivatives and anti her2 antibodies | |
| US20240307541A1 (en) | Methods for local and systemic treatment of cancers, tumors and tumor cells | |
| EP0556285A1 (en) | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents | |
| TW202118518A (zh) | 用於癌症、腫瘤及腫瘤細胞之局部及全身性治療之組合物及方法 | |
| TW202200191A (zh) | 包含含有ｉｌ－２蛋白與ｃｄ８０蛋白之融合蛋白及抗癌藥物的用於治療癌症的藥學組成物 | |
| JPWO2023280880A5 (https=) | ||
| CN1342096A (zh) | 组胺诱导的协同破坏肿瘤作用 | |
| JPH01502909A (ja) | 免疫毒素による人間の治療における免疫抑制 | |
| JP2634218B2 (ja) | Ａｄｃｃ療法を高める組成物 | |
| WO1989011299A1 (en) | Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates | |
| CN1045621C (zh) | 免疫球蛋白结合物的制备方法 | |
| Rogers et al. | Augmentation of in vivo cytotoxic T lymphocyte activity and reduction of tumor growth by large multivalent immunogen | |
| US5762932A (en) | Combined treatment of iron depletion and IgG antibody | |
| Cheung | Immunotherapy: Neuroblastoma as a model | |
| JPWO2023081752A5 (https=) | ||
| Otsuji et al. | The effect of intravenous and intra-tumoural chemotherapy using a monoclonal antibody—Drug conjugate in a xenograft model of pancreatic cancer | |
| Tempero et al. | Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma | |
| JPH07500565A (ja) | 免疫抑制ムチンを生成する腺がんの能動的特異免疫療法 | |
| WO2025056070A1 (zh) | 一种治疗肿瘤的组合疗法及其应用 | |
| Mulshine et al. | In vivo diagnosis and therapy of human tumors with monoclonal antibodies: Selection of antibodies and preliminary clinical studies in small cell carcinoma of the lung | |
| CA2464947C (en) | Combination therapy for treating disease | |
| Otsuji et al. | Biodistribution of monoclonal antibody A7 and its F (ab′) 2 fragment in athymic nude mice bearing human pancreatic carcinoma |